Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Epirium Bio Announces Commencement of Phase 1 Clinical Trial of EPM-01 in Becker Muscular Dystrophy
Details : The Phase 1 open-label, dose-escalation study is evaluating the safety, preliminary clinical efficacy and potential biomarkers of three doses of EPM-01 in participants with Becker or Becker-like muscular dystrophy.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 08, 2020
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Epirium
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Epirium has advanced its first clinical candidate EPM-01 (Epicatechin) in Becker muscular dystrophy and plans to follow with drug development targeting other disorders associated with mitochondrial dysfunction and tissue degeneration.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
August 27, 2020
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Epirium
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 13, 2020
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The company's prior studies have shown that EB 002 can stimulate mitochondrial biogenesis, contributing to the restoration of tissue bioenergetics, thus upregulating key protein production.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 14, 2020
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Cardero Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
(-)- Epicatechin Becker Muscular Dystrophy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 02, 2017
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Cardero Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Cardero Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
November 16, 2016
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Cardero Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Cardero Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
(+) Epicatechin to Treat Friedreich's Ataxia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 21, 2016
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Cardero Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epicatechin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : San Diego Veterans Healthcare System | National Center for Complementary and Integrative Health | University of California, San Diego | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 14, 2016
Lead Product(s) : Epicatechin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : San Diego Veterans Healthcare System | National Center for Complementary and Integrative Health | University of California, San Diego | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epicatechin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : National Institutes of Health | National Center for Complementary and Integrative Health | San Diego Veterans Healthcare System | University of California, San Diego
Deal Size : Inapplicable
Deal Type : Inapplicable
Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 01, 2015
Lead Product(s) : Epicatechin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : National Institutes of Health | National Center for Complementary and Integrative Health | San Diego Veterans Healthcare System | University of California, San Diego
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Cardero Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 17, 2013
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Cardero Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable